Drug Insights

Using Synapse for Your Atomoxetine Research: An Easy Guide

27 March 2024
2 min read

Atomoxetine, a diminutive molecule drug concocted by Eli Lilly, procured its inaugural medical approval in 2002. The drug functions as an inhibitor of norepinephrine reuptake in the brain, inducing augmented levels of norepinephrine in the synaptic cleft. The drug's primary indication is for Attention Deficit Disorder with Hyperactivity (ADHD), a disorder typified by inattentiveness, impulsivity, and hyperactivity. Atomoxetine is postulated to operate by enhancing focus and concentration in individuals grappling with ADHD. Taking everything into account, atomoxetine's intricate mechanism of action and clinical indications proffer it as a valuable therapeutic option for those affected by ADHD. Click on the image below to begin the exploration journey of Atomoxetine through the Synapse database!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

FDA Greenlights NMD670 Phase 2b Trial in US Myasthenia Gravis Patients
Latest Hotspot
3 min read
FDA Greenlights NMD670 Phase 2b Trial in US Myasthenia Gravis Patients
27 March 2024
FDA Approves NMD Pharma's IND Application for Phase 2b Trial of NMD670 in US Myasthenia Gravis Population.
Read →
Bristol Myers Squibb Invests $1.4 Billion in Layout for Schizophrenia Treatment Candidate Drugs
Hot Spotlight
8 min read
Bristol Myers Squibb Invests $1.4 Billion in Layout for Schizophrenia Treatment Candidate Drugs
27 March 2024
On March 18th, Bristol Myers Squibb (BMS) finalized its acquisition of Karuna Therapeutics, enhancing its neuroscience investments. Karuna has stopped NASDAQ trading and is now fully owned by BMS.
Read →
UK's initial participant receives OATD-01 treatment in Phase 2 of the KITE trial targeting lung sarcoidosis
Latest Hotspot
3 min read
UK's initial participant receives OATD-01 treatment in Phase 2 of the KITE trial targeting lung sarcoidosis
27 March 2024
Molecure S.A. is dedicated to finding new treatments for diseases once thought incurable, focusing on small-molecule and mRNA-based drugs. The company is now conducting a Phase II trial of their drug OATD-01 for active pulmonary sarcoidosis.
Read →
Accessing Midodrine Information on Synapse: A Step-by-Step Approach
Drug Insights
2 min read
Accessing Midodrine Information on Synapse: A Step-by-Step Approach
27 March 2024
Midodrine, a diminutive molecule of therapeutic nature, exhibits its therapeutic effect through its agonistic action upon the α-adrenergic receptor.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.